Back |
home / stock / rzlt / rzlt message board
News, Short Squeeze, Breakout and More Instantly...
Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Completed in-vivo toxicology study in brown Norway rats; early results show no abnormalities at highest tested dose of RZ...
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, t...
Shares of Rezolute, Inc. (NASDAQ: RZLT) traded at a new 52-week high today and are currently trading at $2.99. So far today, approximately 207.71k shares have been exchanged, as compared to an average 30-day volume of 238.24k shares. Rezolute, Inc., a clinical stage biopharmaceutical company,...